Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 10:00 AM ET – Factory Orders (MoM) (Apr)

✓ 10:00 AM ET – JOLTs Job Openings (Apr)

✓ 10:00 AM ET – Total Vehicle Sales

✓ 09:45 AM ET – Chicago PMI (May)

✓ 04:30 PM ET – API Weekly Crude Oil Stock

PREMARKET SNAPSHOT 📈

The S&P 500 edged up slightly, the Dow dipped modestly, while the NASDAQ gained a bit.

SECTOR SNAPSHOT ✨

Mixed market with Information Technology and Health Care posting gains, while Energy, Industrials, and Utilities lead the declines.

Pre Market Unusual Volume

📈 MicroAlgo Inc (MLGO): Exhibited an extraordinary trading volume of 13.19 million shares, significantly higher than its average volume of 0.75 million shares. The stock closed at $4.09, marking a substantial increase of 162.18% after company announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center.

📈 Core Scientific Inc (CORZ): Experienced a notable trading volume of 6.20 million shares compared to its average of 3.72 million shares. The stock price stood at $6.90, reflecting an increase of 41.68% after it announced the signing of a series of 12-year contracts with CoreWeave, the AI Hyperscaler.

📈 LuxUrban Hotels Inc (LUXH): Recorded an unusual trading volume of 5.69 million shares, well above its average volume of 1.11 million shares. The stock price rose to $0.33, achieving a gain of 6.72%. LUXH has formed a Special Committee of independent directors to explore strategic initiatives aimed at maximizing shareholder value.

📈 Fresh2 Group Ltd ADR (FRES): Saw an exceptional trading volume of 5.21 million shares, compared to its average volume of 0.10 million shares. The stock price surged to $0.54, with a significant increase of 52.34%.

📈 Wimi Hologram Cloud Inc ADR (WIMI): Reported an unusually high trading volume of 4.11 million shares against its average of 2.62 million shares. The stock closed at $1.04, experiencing an increase of 20.93%. WIMI and MicroAlgo are establishing a micro-consciousness quantum research center, merging disciplines like physics, medicine, genetics, and computer science to focus on consciousness studies.

Premarket Movers

Clean Energy Fuels Corp. (CLNE) is trading at $3.1100 in pre-market, up 6.51% at 7:45 AM EDT after news of expanding its fueling footprint in Southern California.

SunLink Health Systems, Inc. (SSY) is trading at $0.7501 in pre-market, up 24.19% at 7:42 AM EDT after announcing the sale of Trace Extended Care & Rehab.

Important FDA 

Recently Announced

The FDA has been particularly active in recent weeks, delivering a mix of outcomes for biotech companies seeking approval for their innovative treatments.

Bristol-Myers Squibb Co. (BMY) On May 30, 2024, Bristol-Myers Squibb received positive news as the FDA approved the expanded use of Breyanzi for the treatment of relapsed or refractory mantle cell lymphoma. This approval broadens the therapeutic options available for patients battling this aggressive form of cancer.

AstraZeneca PLC (AZN.L, AZN) & Daiichi Sankyo Company Limited (DSKYF.PK) Both AstraZeneca and Daiichi Sankyo celebrated a significant milestone on April 6, 2024, when the FDA approved Enhertu for the expanded treatment of adult patients with unresectable or metastatic HER2-positive solid tumors. This approval marks a major advancement in the treatment options for these patients, as Enhertu is already approved in other countries for similar uses.

Announcing Today

Catalyst Pharmaceutical Partners Inc. (CPRX) Catalyst Pharmaceutical Partners is awaiting an FDA decision today, June 4, 2024, regarding their request to increase the indicated maximum daily dosage of Firdapse Tablets from 80mg to 100mg for the treatment of Lambert-Eaton myasthenic syndrome. This decision is crucial for enhancing treatment options for patients with this rare neurological disorder.

Upcoming Announcements

GSK plc (GSK.L, GSK) Looking ahead, GSK is anticipating a critical FDA decision on June 7, 2024. The agency will decide on the extension of the indication for AREXVY, an adjuvanted respiratory syncytial virus (RSV) vaccine, to adults aged 50-59. This decision could potentially expand the protective reach of this vaccine to a broader age group, enhancing public health defenses against RSV.

Eli Lilly and Co. (LLY) Eli Lilly is also in the spotlight with an upcoming FDA panel review on June 10, 2024, for Donanemab, their treatment for early symptomatic Alzheimer’s disease. This review is a critical step towards providing new hope for patients and families affected by this debilitating condition.

Ipsen SA (IPSEY) Ipsen SA is anticipating an FDA decision on June 10, 2024, regarding Elafibranor, proposed for the second-line treatment of primary biliary cholangitis. This decision is important for advancing treatment options for this chronic liver disease.

Stay tuned for further updates as we continue to track these important FDA decisions and their implications for the biotech industry.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.